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ABSTRACT

Aldharee, Hitham Abdulrahman. M.S. Department of Biochemistry and Molecular
Biology, Wright State University, 2017. Role of ERK3 in regulating RhoGDI1-PAKs
Signaling axis.
Extracellular signal-regulated kinase 3 (ERK3) is an atypical protein kinase of the
mitogen-activated protein kinase (MAPK) family. In comparison to well-investigated
ERK1/2 (classical) MAPKs, much less has been discovered about ERK3 signaling and its
cellular functions. Recent studies have shown that ERK3 is overexpressed in various types
of cancers such as lung cancer and breast cancer and that ERK3 promotes cancer cell
migration and invasion. How ERK3 regulates cancer cell motility and invasiveness,
however, is still largely unknown. RhoGTPases, including Rho, Cdc42 and Rac1, play
critical roles in regulating cell motility and invasiveness through activating downstream
effectors such as p21-activated kinases (PAKs). Rho GTPase-GDP dissociation inhibitor 1
(RhoGDI1) inhibits RhoGTPases’ activity by binding to GDP-bound GTPases and
preventing their activation. Cdc42 and Rac1 are well-known activators of group I PAKs,
including PAK1, PAK2 and PAK3. They activate group I PAKs through binding to the
latter’s auto-inhibitory domains and exposing the auto-phosphorylation residues.
Interestingly, group I PAKs were shown to interact with and phosphorylate ERK3 at S189
of the SEG activation motif. In addition, proteomic analyses of ERK3-interacting proteins
by Yeast-Two-Hybrid screening (Y2H) and Immunoprecipitation-Mass spectrometry (IPMS) revealed that ERK3 interacts with RhoGDI1. These findings raise an intriguing
hypothesis that ERK3 regulates RhoGDI1/RhoGTPases/PAKs signaling pathway, thereby
iii

promoting cancer cell migration. To test this hypothesis, first, we confirmed the
interactions of ERK3 with RhoGDI1, PAKs and Rho GTPases by co-immunoprecipitation
and co-immunofluorescent staining. Interestingly, co-immunofluorescence data showed
that ERK3 co-localizes with RhoGDI1, PAK1 and Cdc42 at the leading edge of the plasma
membrane, suggesting that ERK3 might regulate PAKs’ activation. Indeed, we found that
in both A549 lung cancer cell and MDA-MB231 breast cancer cells, ERK3 greatly
upregulates group I PAKs’ activating phosphorylations at Ser144/Ser141 and
Thr423/Thr402, but has no effect on PAKs’ expression levels. We then sought to elucidate
how ERK3 promotes PAKs’ phosphorylations (activation). By performing Cdc42/Rac1
activation assay we found that ERK3 upregulates the cellular levels of the active forms of
Cdc42 and Rac1 (GTP-Cdc42 and GTP-Rac1), which accounts for the increase of PAKs’
activity. As RhoGDI1 inhibits the activation of Cdc42 and Rac1 via direct binding, we
investigated the effect of ERK3 on their interactions. While exogenous overexpression of
ERK3 did not show clear effect, expression of ERK3 kinase dead mutant (a potential
dominant negative form of ERK3) greatly increased the interaction of RhoGDI1 with Rac,
suggesting a potential role of ERK3 in facilitating the dissociation of RhoGDI1 off Rac.
Mechanistically, our preliminary data of in vitro kinase assay suggests that ERK3 might
phosphorylates RhoGDI1, which may decrease RhoGDI1’s binding with Rac1/Cdc42.
Lastly, we found that ERK3-induced cancer cell migration was almost abolished by the
inhibitors of group I PAKs. In conclusion, these results clearly suggest that ERK3 promotes
cancer cell migration through upregulating group I PAKs signaling.
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I.
i.

Introduction

Mitogen-Activated Protein Kinase Pathways

Mitogen-Activated Protein Kinases (MAPKs) are serine/threonine kinases that
transduce several extracellular signals into intracellular responses (Coulombe and
Meloche, 2007; Bind et al., 2004). MAPKs have been shown to play significant roles in
regulating multiple cellular events, such as cell proliferation, differentiation, apoptosis,
metabolism and motility (Dhillon et al., 2007). Six groups of MAPKs have been identified
in mammals, including extracellular signal–regulated kinases (ERK)-1/2, ERK3/4, ERK5,
ERK7/8, c-Jun N-terminal Kinases (JNK)-1/2/3 and the p38 isoforms α,β,γ, δ (Dhillon et
al., 2007). Based on the activation process and the regulatory mechanisms, MAPKs are
classified into classical (conventional) or non-classical (atypical) kinases (Figure 1,
Coulombe and Meloche et al., 2007). The Conventional MAPKs group consists of four
subgroups: ERK1/2, p38s, JNKs and ERK5. These MAPKs are activated by mitogenic
signals through a cascade that involves MAPK kinase kinase (MAPKK) and MAPK kinase
(Figure 2) that turns in activating MAPKs through phosphorylating a conserved T-X-Y
phosphorylation motif (Kostenko et al., 2012) (Figure1). Importantly, dual threonine/
tyrosine phosphorylations in T-X-Y motif are critical for MAPKs’ activation (Coulombe
and Meloche et al., 2007).The atypical MAPKs group includes four members: ERK3,
ERK4, ERK7 and Nemo-like kinase (NLK). In contrast to classical MAPKs, atypical
MAPKs have a single phosphor acceptor residue and possess glycine or glutamic acid
residues instead of tyrosine in their phosphorylation motif. Interestingly, this group of
1

MAPKs cannot be activated by the mitogenic signals for conventional MAPKs. In
comparison with the well-established conventional MAPKs signaling cascade, much less
is known about atypical MAPKs signaling and functions (Coulombe and Meloche, et al.,
2007).

Figure 1: Schematic representation of human MAPKs structure.

The composition of MAP kinases is shown as N- and C-terminal extensions of
variable lengths surrounding a kinase domain (in blue). NLS: nuclear localization
sequence; TAD, transactivation domain; C34: conserved region in ERK3/4; AHQr: alanine
(A), histidine (H) and glutamine (Q) rich domain. Numbers in the kinase domains indicate
the percentage of homology each MAPK has in its kinase domain relative to that of ERK1
(Coulombe and Meloche et al., 2007).

2

Figure 2: Schematic presentation of distinct MAPK signaling pathways in human.

ii.

ERK3

Extracellular Regulated Kinase 3 (ERK3) is a member of a typical MAPK (Coulombe
and Meloche et al., 2007). ERK3 gene was cloned in the early 1990s using an ERK1
derived probe (Boulton, et al., 1991). ERK3 protein contains 721 amino acids, but shows
a molecular mass of 100 kDa possibly due to posttranslational modifications. ERK3 protein
highly unstable with a half-life of 30 minutes (Turgeon et al., 2000). It has been shown that
ERK3 mRNA is expressed ubiquitously in all mammalian tissues with the highest
expression in the brain, skeletal muscle and gastrointestinal tract (Turgeon et al., 2000).
ERK3 protein structure is composed of a kinase domain at the amino terminus followed
with a central C34 (conserved in ERK3/4) domain and a unique very long carboxy terminal
domain that is not shown in classical MAPKs (Figure 1, Coulombe and Meloche et al.,
2007). Interestingly, on the contrary to conventional MAPKs such as ERK1/2, ERK3
3

possesses a single Ser-Glu-Gly (SEG) phospho-acceptor motif in its activation loop,
instead of the Thr-X-Tyr (TXY). ERK3 and ERK4 have the so-called C34 domain, whose
biochemical and cellular functions are unclear. The c-terminus of ERK3 is
hyperphosphorylated during mitosis, which is important for ERK3 protein stability
(Tanguay, Rodier, and Meloche. 2010). However, more studies need to be done to explore
the importance of the unique C- terminal domain in ERK3 that is not conserved in classical
MAPKs and ERK4 (Figure 1, Coulombe and Meloche et al., 2007).
Little is known about the activation of ERK3 kinase. Thus far, no upstream cellular
stimulus has been identified for ERK3 activation. S189 within the SEG activation motif of
ERK3 is known to be phosphorylated by ERK3 itself (Coulombe and Meloche et al., 2007)
(Cheng et al., 1996) and by group I p21-activated kinases (PAK1, 2, and 3) (Mota-Peynado,
et al., 2011; Déléris, et al., 2011), which presumably enhances ERK3 kinase activity.
Besides S189 phosphorylation, ERK3 is regulated on gene expression and protein stability
(Coulombe and Meloche et al., 2007). ERK3 expression is shown to be upregulated by
BRAF in melanoma (Hoeflich et al., 2006) and by BMI1 (via derepressing ERK3 targeted
by let7i miRNA) in head and neck cancers (Elkhadragy et al., 2017). ERK3’s expression
level and functions are also regulated by protein stability through ubiquitination-dependent
proteasome degradation pathway (Coulombe et al., 2003, 2004). In addition, ERK3 protein
has been shown to be localized in the nucleus and cytoplasm and at the leading edge of the
plasma membrane of migrating cells (Bind et al., 2004; Julien et al., 2003; Schumacher et
al., 2004). ERK3 can be translocated from the nucleus to the cytoplasm and its nuclear
export is mediated by CRM1 (Déléris, et al., 2008)
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iii.

Physiological functions of ERK3

Various physiological roles, including development and immune functions, have
been revealed for EKR3 in mammalian cells. Neonate mice with homozygous ERK3 gene
disruption (ERK3 -/-) die soon after birth due to lung maturation defect and acute
respiratory system malfunction, suggesting that ERK3 is important for lung maturation and
function (Klinger S et al., 2009). In addition, ERK3 -/- mice had reduced weights of fetal
liver, lung and heart.
ERK3 also has been reported to regulate T-cell activation and development. Two
Studies (Marquis et al., 2014; Sirois et al., 2015) reported that T cells showed a reduced
level in activation and proliferation in ERK3-deficient condition, accompanied by
abnormal cytokines secretion. These findings suggest that ERK3 is involved in regulating
TCR-induced T cell activation. In addition, insulin secretion in β-islet cells was decreased
by ERK3 depletion (Anhe et al., 2006). Moreover, ERK3 is induced by pro-inflammatory
cytokines and promotes endothelial cells migration and proliferation through regulating
SRC-3/SP-1-mediated VEGFR2 expression (Wang et al., 2014). Furthermore, ERK3
interacts with hCdc14A (a member of the dual-specificity phosphatase family) and is
localized to mitotic spindles during mitosis and may regulate cells division and
differentiation (Hansen et al., 2008).
ERK3/ERK4 were identified as substrates of group I p21-activated kinases (PAKs).
PAKs (1/2/3) directly phosphorylate ERK3 and ERK4 at S189 and S186 residues,
respectively in their activation loop (Déléris, et al., 2011). Phosphorylations of ERK3 and
ERK4 at this residue enhances their interactions with MAPK-activated protein kinase-5
(MK5), leading to MK5’s kinase activation and phosphorylation at Thr182 (Seternes OM
5

et al., 2004; Schumacher S et al., 2004). It remains controversial whether or not ERK3
directly phosphorylates MK5 at Thr182. The study by Seternes et al claimed that MK5 is
a direct substrate of ERK3, whereas the study by Schumacher S et al. demonstrated that
ERK3 (or ERK4) increased MK5’s T182 phosphorylation by promoting MK’s
autophosphorylation on this residue.
iv.

ERK3’s roles in cancers

The conventional MAPKs have been well studied in cancer cells and shown to play
critical roles in a variety of processes, including proliferation, survival and
migration/invasion (Kostenko, Dumitriu, and Moens 2012).The involvement of atypical
MAPKs in tumorigenesis has just emerged recently. Accumulating studies have
demonstrated the importance of ERK3 signaling in cancers. ERK3 expression level has
been reported to be upregulated in multiple types of cancers, including lung cancer (Long
et al., 2012), oral squamous cell carcinoma (Rai R et al., 2004) and gastric cancer tissues
(Kostenko S et al., 2012). At cellular levels, ERK3 promotes migration and invasion of
lung cancer cells and breast cancer cells (Long et al 2012; Almahdi et al, 2015). In breast
cancer cells, ERK3 localizes mainly in the nucleus, but also at the leading edge of the
plasma membrane. Of particular interest, ERK3 was shown to localize in the lamellipodia
structure which is known as cell protrusion structure and critical for cancer cell migration
(Almahdi et al, 2015). In the same study, ERK3 overexpression was shown to alter cell
morphology by regulating cell adhesion and spreading. Taken together, these findings
suggest that ERK3 plays important roles in cell morphology and migration.
ERK3 also promotes cancer cell invasion. A study by (Long et al 2012) showed
that ERK3 directly binds to steroid receptor co-activator (SRC-3) and phosphorylates S857
6

residue which is essential for SRC3 to interact with the ETS transcription factor PEA3 and
form the ERK3/SRC-3/PEA3 complex. As a consequence, the expression of matrix
metalloproteinases (MMPs) are upregulated via this transcriptional complex (SRC3/PEA3), which turns in promoting cancer cells invasiveness.
v.

PAKs

The p21-activated kinases (PAKs) are serine/threonine kinases that participate in
various cellular events (Dan et al., 2001; Knaus and Bokoch, 1998). They are conserved in
yeast and Drosophila (Bokoch et al., 2003). PAKs consist of 545 amino acid with a
molecular mass of 65-74 kDa. In 1994, PAKs were discovered and identified as small
GTPases binding proteins when scientists were looking for Rac and Cdc42 targets (Manser
et al., 1994). The p21 small GTPases (Rac/Cdc42) were later found to be PAKs’ bona fide
activators (Rudel and Bokoch 1997; Bokoch et al., 1998). Based on their protein structures
and the regulatory mechanisms, mammalian PAKs are divided into two groups, group I
(PAK1, PAK2, and PAK3) and group II (PAK4, PAK5, and PAK6) (Sells et al., 1997;
Manser et al., 1997).
Group I PAKs (PAK1, PAK2, and PAK3) are mainly expressed in brain, muscle,
and spleen in mammalian tissues. They possess a p21-binding domain (PBD) or Cdc42/Rac
interacting domain (CRID) that overlaps with the auto-inhibitory domain (AID) near the
N-terminal region (Figure 3, Manser and Zhao. 2005). Right after the PBD domain is the
lipid binding motif where phospholipids such as phosphatidic acid (PA) can bind and
activate these kinases (Abramovici et al., 2009). In addition, a SH3 binding site which is
known as a binding domain for PAK-interacting exchange factor (PIX) is conserved in the
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regulatory domain. The C-terminal catalytic domain is 90 % identical in PAK1, PAK2, and
PAK3 (Nicholas et al., 2014).

Figure 3: Structure of group I (PAK1, PAK2, PAK3) p21-activated kinases.

Group I PAKs have multiple auto- and trans-phosphorylation residues which are
located in both the regulatory domain and the catalytic domain (Figure 3). These
phosphorylation sites play roles in protein-protein interaction and kinases activation
through relieving the auto-inhibition of PAKs. PAK1/PAK3 possess S144 (S141 for
PAK2) auto-phosphorylation residue in their regulatory domains that is critical for kinase
activation (Parrini et al., 2002; Pirruccello et al., 2006). Thr 423 of PAK1/PAK3 (Thr 420
for PAK2) is a trans-phosphorylation residue that is located in the catalytic domain and

8

participates in PAKs’ activation through preventing dimerization (Parrini et al., 2002;
Pirruccello et al., 2006). It is important to point out that this is the only phosphorylation
site identified in the catalytic domain of PAK1/2/3 (Parrini et al., 2002; Pirruccello et al.,
2006). Several other autophosphorylation sites in the N-terminal regulatory region, such as
Ser199, Ser204, Ser192 and Ser197, have been reported to be involved in PAKs’
interactions with other proteins and the kinase activity (Manser et al., 1997; Gatti et al.,
1999).
vi.

Regulation of Group I PAKs Activation

PAKs’ activation is regulated by the modification of group I PAKs’ activation loop
and the subsequent conformational change of protein structure. Inactive group I PAKs exist
as homodimers in cells. The dimerization causes trans-inhibition conformation in which
the auto-inhibitory domain (AID) in the amino terminal region of one molecule binds to
and inhibits the catalytic domain of the other (Figure 3, Lei et al., 2000, Manser and Zhao.
2005). Under trans-inhibition conformation, the phosphorylation residues in both the
regulatory domain and the catalytic domain are not exposed and thus unable to be
phosphorylated for activating PAKs.
PAKs can be activated by the binding of the active form of small GTPases (GTPRac/ GTP-Cdc42) to CRID. Binding of Rho-GTPases disrupts the PAKs’ dimerization and
activates PAKs through exposing the auto- and trans-phosphorylation residues (S144 and
Thr 423 for PAK1/3 and S141 and Thr 420 for PAK2). The phosphorylations of S141 and
S144 in the regulatory domain partially activate kinases, followed by the subsequent
phosphorylations of Thr420 and Thr423 residues in the catalytic domain and the full
activation of PAKs activation. GTPases-dependent group I PAKs’ activation occurs in
9

responses to growth factors, such as EGF and VEGF, that activate Rac and Cdc42 through
a guanine nucleotide exchange factor (GEF) (Gatti et al., 1999; Bagheri et al., 2000; Chong
et al., 2001; Parrini et al., 2002; Pirruccello et al., 2006).
Besides activation via small GTPases, GTPase-independent mechanisms have been
reported for activating PAKs. Pyruvate dehydrogenase kinase 1 (PDK1) phosphorylates
Thr 423 of PAK1/3 (Thr 420 of PAK2) and activates these PAKs (King et al., 2000). Group
I PAKs also can be activated when phospholipids, such as phosphatidic acid (PA), bind to
the lipid binding motif and cause conformational change that disturbs kinases’ dimerization
(Abramovici et al., 2009). Sphingolipids were also shown to activate group I PAKs though
a similar mechanism (King et al., 2000). Moreover, Cyclin-dependent kinase 5 (Cdk5) and
Cdc2 phosphorylate Thr212, which disrupts PAKs’ homodimerization and enhances
kinases’ activation (Thiel et al., 2002). On the other hand, group I PAKs are negatively
regulated via several mechanisms. For instance, the binding of Pak-interacting protein
(PIP) to CRID/PBD inhibits PAKs activation and signaling (Xia et al., 2001).
vii.

Physiological Roles of Group I PAKs

PAKs are involved in regulating a wide variety of cellular events such as
cytoskeletal remodeling, cell motility, proliferation and cell survival. A pioneering study
(Sells et al., 1997) shows that PAK1 promoted the formation of lamellipodia and filopodia
structures which are important for cells to migrate. In the same study, PAK1 was shown to
also localize at focal adhesions and control stress fiber formation. P21- activated kinases
(PAK1, 2, 3) have several downstream targets that control cytoskeletal remodeling and cell
motility, such as merlin, filamin, myosin light chain kinase, and LIM kinase (Rane and
Minden. 2014).
10

Group I PAKs are involved in the regulation of MAPK signaling pathways. PAKs
are known to activate ERK1/2 in response to growth factors and extracellular matrix signals
(Beeser et al., 2005; Park et al., 2007). As mentioned above, PAK1/2/3 were recently found
to also phosphorylate ERK3 and ERK4 on their activation loop at S189 and S186 residues,
respectively, which turns in activating MK5, an downstream effector of ERK3 and ERK4
(Déléris, et al., 2011). As to the role in cell survival, PAK1 negatively regulates proapoptotic proteins dynein light chain 1 (DLC1) and BimL, by which PAK1 downregulates
apoptosis (Vadlamudi et al., 2004). Furthermore, cell cycle progression is promoted when
PAK1 activates the transcription factor NFkappaB and upregulates transcriptional level of
cycling D1 (Dadke et al., 2003).
Owning to their essential roles in regulating cell morphology, motility and survival,
group I PAKs play different biological roles in regulating development and metabolism.
For example, PAK2 knock-out mice have embryonic lethal abnormalities suggesting that
it plays critical function in embryogenesis (Qu et al., 2011; Arias and Chernoff 2008).
While PAK1 knockout mice show no clear developmental defect, PAK1 level was shown
to be downregulated in type 2 diabetic mice and may play an important role in glucose
homeostasis (Wang et al., 2011). In addition, group I PAKs are important for heart muscle
development and functions (Egom et al ., 2010; Ai et al ., 2011).
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viii.

Group I PAKs Roles in Cancer

The implications of group I PAKs (especially PAK1) have been well studied and
identified as oncogenic proteins in multiple types of cancers. They promote cancer cell
migration, proliferation, differentiation, as well as tumor growth and metastasis. Group I
PAKs have been shown to be overexpressed and/or highly activated in cancers (Liu et al,
2016).
In breast cancer, about 50 % of breast tumors show hyperactivated and/or highly
expressed PAK1 (Maroto et al, 2008). Furthermore, cancer cell migration, survival and
colony formation are promoted by PAK1 through regulating the Wnt, Erk and Akt
pathways (Ye DZ and Field J, 2012). In melanoma, PAK1 expression level is positively
regulated by BRAF point mutation (V600E), a major cause of this type of cancer
(Maldonado et al., 2003). In addition, group I PAKs are upregulated in non-small cell lung
cancer (NSCLC) patients with metastasis as a result of altered epidermal-growth factor
receptor (EGFR) signaling (Liu et al., 2016). EGFR signaling stimulates the activation of
Rho-GTPases (such as Rac/Cdc42) which are activators of PAKs. Rho GTPases activate
group I PAKs, thereby promoting NSCLC migration and proliferation. The combination
of Group I PAKs inhibitor (IPA3) and EGFR-ITK (Gefitinib) greatly inhibited cancer cell
proliferation and tumor growth. These findings suggest that group I p21-activated kinases
(PAK1, PAK2, and PAK3) promote lung tumor formation and metastasis (Liu et al., 2016).
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ix.

Rho Family GTPases (Rho GTPases)
Rho GTPases comprise a family of low molecular weight switches that are involved

in regulating several cellular aspects such as cell migration, proliferation, and cytoskeletal
remolding (Ridley and Hall 1992; Ridley et al., 1992; Raftopoulou and Hall 2004). Rho
sub-family belongs to Ras superfamily which consists of five sub-families (Boureux et al.,
2007) Rho family of GTPases was first discovered and identified in Aplysia ((Madaul and
Axel, 1985). Later on, Rho genes were uncovered in yeast, Drosophila, rat and human. Rho
sub-family consists of small GTPases including Rho, Rac and Cdc42. Rac1 and Cdc42
were discovered in 1989 and 1990, respectively (Didsbury et al., 1989; Munemitsu et al.,
1990). Rho GTPases share several common properties, such as their molecular weight
(about 21 kDa), containing a GTPase, and the presence of the C-terminal domain which
facilitates the localization of Rho proteins at the plasma membrane (Madaul and Axel,
1985).
Rho GTPases’ activation is regulated through three main regulators: guanine
nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs) and guanine
nucleotide dissociation inhibitors (GDIs) (Madaul and Axel, 1985). The action of (GEF) is
required to catalyze the exchanging of the cytosolic GDP-bound inactive state of small
GTPases to the GTP-bound active state. The activation process occurs at the plasma
membrane as a response to various receptors signaling such as epidermal growth factor
receptor (EGFR) and G-protein coupled receptor (GPCR). On the contrary, these GTPases
are inactivated by the action of (GAPs) which catalyzes the hydrolysis of GTP-bound
active form to GDP-bound inactive form. Lastly, GDIs are known to negatively regulate
small GTPases’ activation through binding to GDP-bound GTPases and preventing
13

GTPases’ plasma membrane translocation and activation that is executed by GEFs (Figure
3, Huveneers and Danen, 2009). Three isoforms of RhoGDI have been identified: the
ubiquitously expressed isoform 1 (RhoGDI1) (Fukumoto et al., 1990), RhoGDI2 and
RhoGDI3 which are expressed manly in brain and lung (Adra et al., 1997; Zalcman et al.,
1996).
RhoGDIs regulate the shuttling of small GTPases (Cdc42 and Rac) between the
cytosol and the plasma membrane, which is critical for GTPases’ activation/inactivation
cycling catalyzed by GEF and GAP (Adra et al., 1997; Sasaki et al., 1998; Olofsson 1998;
Golovanov 2001) Thus, the dissociation rate of the GTPases from RhoGDI tightly controls
the activation of GTPases and the downstream PAKs. Interestingly, the association of
RhoGDIs with Rho-GTPases is regulated by PAKs and other kinases (DerMardirossian et
al. 2004) .For instance, PAK1 phosphorylates RhoGDI1 at two essential residues (S101
and S174) both in vitro and in vivo, altering its conformation and promoting the
dissociation of Rac1 (DerMardirossian et al. 2004). In addition, Src kinase phosphorylates
RhoGDI at Tyr156 residue, which significantly reduces the re-association of RhoA, Cdc42
and Rac1 with RhoGDI (DerMardirossian et al. 2006).
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Figure 4: Activation/Inactivation cycle of Rho-GTPases
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x.

Hypothesis and specific aims
ERK3 promotes both migration and invasion of cancer cells. While ERK3 is known

to phosphorylate SRC-3 and upregulate SRC-3-mediated expression of MMPs that are
important for cell invasion, how ERK3 regulates cell morphology and motility is unclear.
Two recent studies showed that ERK3 interact with PAKs, the master regulators of cell
morphology and motility (Déléris, et al., 2011; Almahdi et al., 2015). In addition, both
Yeast two hybrid (Y2H) screening (Vinayagam et al., 2011) and immunoprecipitationmass spectrometry (IP-MS) analysis (unpublished data from our laboratory) identified
RhoGDI1 as an interacting partner of ERK3 protein. Given that RhoGDI1 acts as an
inhibitor of RhoGTPases and the downstream PAKs, these findings raise an intriguing
hypothesis that ERK3 upregulates group I PAKs’ activation through targeting
RhoGDI1/RhoGTPases signaling axis, thereby promoting cancer cell motility. Precisely,
this study aimed to identify a downstream target (pathway) of ERK3 by which it promotes
cancer cell migration. Three aims are proposed to test the hypothesis: (1) To determine the
role of ERK3 in regulating group I PAKs’ activity (phosphorylations); (2) To determine
the underlying mechanisms by which ERK3 regulates PAKs’ activity; (3) To determine
whether ERK3 and Group I PAKs cooperatively regulate cell migration.
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II.
i.

Materials and Methods

Cell culture

Human cervical cancer cell line Hela, breast cancer cell line MDA-MB231 and lung
cancer cell line A549 were purchased from American Type Culture Collection (ATCC).
A549 cells were maintained in RPMI 1640 medium supplemented with 10% FBS. HeLa
and MDA-MB213 cells were cultured in Dulbecco’s modified Eagle medium
supplemented with 10% FBS. All the culture media and supplements were purchased from
Life Technologies/Invitrogen.

ii.

DNA constructs

To generate pSG5-RhoGDI1-HA, first, full length RhoGDI1 cDNA was amplified
from pCMV-XL5-RhoGDI1 (kindly provided by Dr. Julian Cambronero’s Lab) using the
following

primers

containing

TGGCTGAGCAGGAGCCCACA-3’

a

KpnI
and

restriction

site:

5’GGGGTACCA

5’GGGGTACCTCAGTCCTTCCAGTCC

TTCTTG-3’. pSG5-RhoGDI1-HA was then generated by ligating RhoGDI1 fragment into
pSG5-KHMA2M1-HA following KpnI digestion. To generate pET-28b (+) RhoGDI1-His,
full length RhoGDI1 cDNA was amplified from pCMV-XL5-RhoGDI1 using the
following

primers

containing

5’CGGAATTCGATGGCTGAGCAGGAGCCCAC-3’

ECORI
and

sites:

5’CGGAATTCTCAGTC

TCCAGTCCTTCTTG-3’. pET-28b (+) RhoGDI1-His was then generated by ligating
RhoGDI1 fragment into pET-28b (+)-His following ECOR I digestion.
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iii.

Proteins expression and purification

Full length ERK3 kinase was expressed and purified in Sf9 insect cells as described
previously (Seterns et al., 2004). RhoGDI1-His was expressed in E. coli (BL21) following
the transformation with pET-28b (+) RhoGDI1-His plasmid, then purified using NickelNTA His-tagged proteins purification kit (Millipore Sigma, USA) following the
manufacturer’s protocol.

iv.

Plasmids and siRNAs transfections

Transient transfections with plasmids were performed using Lipofectamine 3000
Reagent (Invitrogen/ThermoFisher Scientiﬁc, Carlsbad, CA, USA) or FuGENE HD
transfection reagent (Active motiv, USA). siRNA transfections were performed using
Dharma-FECT Transfection Reagent (Dharmacon, Lafayette, CO, USA), following the
manufacturer’s instructions. The silencer select siRNA targeting human ERK3 and the
Silencer Negative Control #1 were purchased from Ambion/ThermoFisher Scientiﬁc
(Waltham, MA, USA). Unless specifically indicated, cells were harvested for various
analyses 48 hours after transfection.
v.

Generation of breast cancer cell pools stably expressing shRNAs by
lentiviral transduction

MDA-MD231 cell line with stable knockdown of endogenous ERK3 by lentiviral
transduction of a short hairpin RNA (shRNA) specifically targeting ERK3 mRNA
(shERK3). Stable cell pools expressing the non-targeting shRNA (shGIPZ) were used as a
control. The pseudo-lentiviruses were produced in 293T cells by co-expression of
constructs expressing shRNA and Trans-Lentiviral packaging plasmid mix (Open
Biosystems). Pseudoviral particles were harvested 48 hrs post-transfection and
18

concentrated using PEG-it virus precipitation solution (System Biosciences) by following
the manufacturer’s instructions. Cells were transduced with prepared virus in the presence
of polybrene (5 μg/ml). Two days post- transduction, cells were split and selected by
puromycin (1 μg/ml) for 10 days. Knockdown of the targeted genes’ expression was
verified by Western blotting analysis.

vi.

Western blotting

Cells were lysed with EBC lysis buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 0.5%
NP-40, 1 mM complete protease inhibitors [Roche Diagnostics] and 1 mM Phosphatase
Inhibitor Cocktail III [Sigma-Aldrich]). Protein lysates were mixed with 5X SDS sample
buffer and boiled then resolved on 12% SDS-PAGE gels. Western blotting was performed
by first blocking nitrocellulose membranes with 5% non-fat milk in PBS-T buffer for
30minutes, followed by overnight incubation with the primary antibodies at 4°C and 1 hour
incubation with appropriate secondary antibody at room temperature. The Western blot
was visualized by chemiluminescence (Thermo Scientific). The following primary
antibodies were used in Western blotting: anti-ERK3 (Abcam), anti-p-ERK3 (S189)
(generated in our lab), anti-p- PAK1/3 (Thr423)/PAK2 (Thr402) (Cell Signaling
Technology), anti-p- PAK1/3 (Ser144)/PAK2 (Ser141) (Cell Signaling Technology), antiPAK1, 2, 3 (Cell Signaling Technology), anti-Rac1, 2, 3 (Cell Signaling Technology), antiRhoGDI1 (Cell Signaling Technology), anti-Cdc42 (Cell Signaling Technology) and anti–
β-actin (Sigma).
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vii. Immunofluorescence
HeLa and A549 cells were transiently transfected with pSG5-ERK3-HA, pcDNAERK3-MYC, pcDNA-PAK1-MYC, pcDNA-Cdc42-MYC, or pcDNA-RhoGDI. Two days
later, cells were analyzed by immunofluorescent staining using primary mouse anti- myc
antibody (Cell Signaling Technology), rabbit anti-RhoGDI (Cell Signaling Technology),
or rabbit anti-ERK3 (Abcam) and fluorescein-conjugated goat-anti-mouse or goat-antirabbit secondary antibody. Cell nucleus was labelled by DAPI (1μg/ml) staining of DNA.
Images were captured with a Leica CTR 6000 Microscope (Leica Microsystems) and
analyzed using ImagePro 6.2 software (Media Cybernetics).

viii. Two-chamber transwell cell migration assay
Cell migration was analyzed using a modified 2-chamber transwell system (BD
Biosciences), following the manufacturer’s instructions. Cells were detached by trypsinEDTA, washed once with 1× PBS, and then resuspended in serum-free medium. 0.6 ml of
complete culture media with 10% FBS was added to each bottom well. A549 Cells were
added in each transwell insert and allowed to migrate for 17 hours in a 37°C cell incubator.
Cells in the upper surface of the transwell were removed using cotton swabs. Migrated
cells attached on the undersurface were fixed with 4% paraformaldehyde for 10 minutes
and stained with crystal violet solution (0.5% in water) for 10 minutes. Migrated cells were
then photographed and counted under a microscope at 50 X magnification.
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ix.

Cdc42/Rac1 Activation Assay

Cells were lysed with cell lysis buffer (provided with the kit). Cell lysates were
incubated with agarose beads bound with the p21-GTPase binding domain of PAKs (PAKPBD) for 1 h at 4°C for pulling down GTP-bound Cdc42 and Rac1 using Cdc42/Rac1
Activation Assay kit (Cytoskeleton, Inc) following the manufacturer’s instructions. GTPRac1 or GTP-Cdc42 was detected by Western blotting using the anti-Rac1 or anti-Cdc42
antibody provided in the kit.
x.

Immunoprecipitation

Cells were lysed with EBC lysis buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 0.5%
NP-40, 1 mM PMSF, 1 mM Complete protease inhibitors [Roche Diagnostics], 10 mM
NaF, 1 mM sodium orthovanadate, and 1 mM Phosphatase Inhibitor Cocktail III [SigmaAldrich]). One mg of total protein lysate of A549 cells was used for each
immunoprecipitation using 2 µg of ERK3 antibody (Bethyl Laboratories) or normal rabbit
IgG (Santa Cruz Biotechnology). The supernatant was precleared with 30 μl protein A/G
agarose beads for 40 minutes at 4°C with constant rotation. The samples were then
incubated with the desired Ab for 1.5 hours, followed by the addition of 30 μl protein A/G
agarose beads for additional 1 hour. The beads were washed 3 times (10 minutes per wash)
with lysis buffer. Proteins were boiled off the beads in 2× SDS sample buffer and resolved
on 12% SDS-PAGE gel. 2% of the amount of protein supernatant for immunoprecipitation
was loaded as the input control. Western blotting was performed as described previously.
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xi.

In vitro ERK3 kinase assay

The in vitro kinase assay was carried out in 40 mM Tris HCl (pH 7.5), 10 mM
MgCl2, 0.1 mM EGTA, 1 mM dithiothreitol, and 5 mM β-glycero-phosphate. Each
reaction contained 100 ng of purified ERK3 or ERK3KD and 500 ng of the purified protein
substrate RhoGDI1-His, 5 μCi

P-ATP (Perkin Elmer) and 25 μM cold ATP in a total
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volume of 30 μl. The reaction was carried out at 30 °C for 30 minutes and then stopped by
adding 5X SDS sample buffer and boiling the samples. Proteins were resolved by SDSPAGE gel, stained with Coomassie Brilliant Blue (Bio-Rad) and visualized by
autoradiography.
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xii.

Statistics

Results are expressed as mean ± SEM. Statistical significance was determined by a 2tailed Student’s t test. A P value of less than 0.05 was considered statistically significant.
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III.
i.

Results

ERK3 interacts with RhoGDI1 and forms a complex with small-GTPases
and PAK1 in A549 cells.
Cellular signals are relayed through protein-protein interactions which transduce

extracellular signals into intracellular events. We identified RhoGDI1 as an interacting
partner of ERK3 both from our own IP-MS analysis of ERK3 interacting proteins and in a
published Yeast-two-hybrid screening dataset (Vinayagam et al., 2011) that was deposited
in BioGRID (Biological General Repository for Interaction Databases). Therefore, we
wanted to validate the interaction between ERK3 and RhoGDI1 in cells. First, we analyzed
the interaction between these two proteins at the endogenous level. Endogenous ERK3 in
A549 lung cancer cells was immunoprecipitated using rabbit anti-ERK3 Ab and the
presence of RhoGDI1 in the immune-complex was analysed by Western blotting. Indeed,
RhoGDI1 was shown to be co-immunoprecipitated with ERK3 in A549 cells (Figure 5A).
We then wanted to determine the effect of ERK3’s kinase activity on its interaction with
RhoGDI1. RhoGDI1-HA was transiently expressed in stable A549 cells that were
transduced with lentivirus vector CDH, CDH-ERK3-WT, or CDH-ERK3-KD. The
interaction between RhoGDI1 and ERK3 was analysed by pulling down RhoGDI1 using
anti-HA conjugated beads, followed by Western blotting. Interestingly, increased
interaction between RhoGDI1 and ERK3 was detected under the condition of
overexpression of wild type ERK3 in comparison with CDH empty vector (Figure 5B). In
contrast, no ERK3 was pulled down together with RhoGDI1 in cells with overexpression
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of kinase dead ERK3 (ERK3KD). These results suggest that ERK3-RhoGDI1 interaction
is dependent on ERK3 kinase activity.
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Figure 5: ERK3 interacts with RhoGDI1 in a kinase-dependent mechanism in A549
cells. (A) Co-IP and Western blotting analyse of the interaction of endogenous ERK3 with
RhoGDI1. IP was done with a mouse anti-ERK3 antibody, followed by immunoblotting
with either a rabbit anti-ERK3 antibody or an anti-RhoGDI1 antibody. 2% of cell lysate
was loaded as input. (B) Co-IP/Western blotting analyses of overexpressed ERK3 and
RhoGDI1 proteins. pSG5-RhoGDI1-HA was transiently transfected into stable A549 cells
that were transduced with lentiviruses either expressing the CDH empty vector, wild type
ERK3 or kinase dead ERK3 (KD). IP was done using Anti-HA coated agarose beads
followed with immunoblotting with rabbit anti-ERK3 and anti-RhoGDI1 antibodies.
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ii.

ERK3 co-localizes with RhoGDI1, PAK1 and Cdc42 in Hela and A549 cells.
ERK3 was shown to localize in the nucleus and the cytoplasm (Déléris et al., 2008)

and at the leading edge of the plasma membrane (Almahdi et al, 2015). The sub-cellular
distribution of ERK3 can provide hints for explaining how ERK3 participates in different
cellular events such as cell migration. Thus, we wanted to investigate whether there is colocalization of ERK3 with RhoGDI1/cdc42 GTPase/PAK1 complex that play critical roles
in regulating cell motility. For this purpose, both Hela cells and A549 cells were cotransfected with pSG5-ERK3-HA plus pcDNA-Cdc42-MYC, pSG5-ERK3-HA plus
pcDNA-PAK1-MYC, or pcDNA-ERK3-MYC plus pSG5-RhoGDI1-HA plasmids. The
subcellular co-localization of these proteins was examined by immunofluorescence
microscopy (Figure 6). In line with previous studies, ERK3 was seen to localize in the
nucleus, the cytoplasm and the plasma membrane of transfected cells. Interestingly, ERK3
co-localizes with Cdc42, PAK1 and RhoGDI1 at the leading edge of the plasma membrane
(pointed by arrows) in both HeLa (Figure 6A) and A549 (Figure 6B). Of particular note,
Cdc42 overexpression induced the formation of filopodia in both cell lines, where Cdc42
and ERK3 co-localize, suggesting that ERK3 and Cdc42 may cooperatively regulate
cytoskeletal structure and cell migration (the left panels, Figure 6A and 6B).
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Figure 6: Immunofluorescent analyses of the subcellular distribution and colocalization of exogenously expressed ERK3, PAK1, Cdc42 and RhoGDI1 proteins.
HeLa (Figure 6A) and A549 (Figure 6B) cells were transiently co-transfected with pSG5ERK3-HA plus pcDNA-Cdc42-MYC (panels on the left), pSG5-ERK3-HA plus pcDNAPAK1-MYC (panels in the middle), or pcDNA-ERK3-MYC plus pSG5-RhoGDI1-HA
plasmids (panels on the right). Two days after transfection, cells were immuno-stained
with an anti-Myc Ab for the detection of Myc-tagged cdc42, PAK1 and ERK3 proteins,
with an anti-ERK3 Ab for detecting HA-ERK3 protein (green), or an anti-RhoGDI1
(green) Ab for the detection of HA-RhoGDI1. Cell nucleus was marked by DAPI staining
(Blue). Pictures were taken under 63X magnification.
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iii.

ERK3 positively regulates group I PAKs’ activation (phosphorylations) in
A549 cells.
Group I PAKs phosphorylate ERK3 and ERK4 at the SEG activation motif and

upregulates their kinase activities and cellular functions (Déléris, et al., 2011). Owing to
the fact that ERK3 interacts with RhoGDI1, Cdc42 GTPase and PAK1 at the leading edge
of the plasma membrane, we were interested in investigating whether ERK3 upregulates
group I PAKs’ activity as a positive feedback. We either transiently knocked down
endogenous ERK3 using siERK3 (Figure 7A) or overexpressed ERK3 by transfecting
pSG5-ERK3-HA plasmid (Figure 7B) in A549 cells. We found that ERK3 knockdown
greatly decreased phosphorylations of PAK1/3 at Ser144 and Thr423 and PAK2 at Ser141
and Thr402, but caused little change at total levels of PAKs (Figure 7A). ERK3
overexpression increased phosphorylations of PAK1/2/3 at Ser144 and Ser141, but had no
clear effects on the phosphorylations at Thr423/Thr402 and total protein levels of PAKs
(Figure 7B). Overall, these results suggest that ERK3 upregulates group I PAKs’
phosphorylations (indicators of kinase activation) but has little effect on their expression
levels.
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Figure 7: ERK3 upregulates group I PAKs’ activation (phosphorylations) in A549
cells. (A) A549 Cells were transiently transfected with either 20 nM non-targeting control
siRNA (SiCtrl) or ERK3 siRNA (SiERK3). (B) A549 Cells were transiently transfected
with either pSG5-HA empty vector (EV) or pSG5-ERK3-HA construct. For both
conditions, cells were harvested 48 hours post-transfections. Phosphorylations and total
protein expression levels of PAKs1/2/3 were analyzed by Western blotting using antiphospho-PAK1/3(Thr423)/PAK2(Thr402), anti-phosho-PAK1/3(Ser144)/PAK2(Ser141)
and an antibody recognizing PAK1/2/3, respectively. β-Actin was probed to serve as a
loading control.
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iv.

ERK3 positively regulates group I PAKs activation (phosphorylations) in
MDA-MB 231 cells.
After we found that ERK3 upregulates group I PAKs’ phosphorylation in lung

cancer cells, we were interested in confirming this finding in another type of cancer cells.
Given our research focus on the interplay of ERK3 and PAK signaling in cancer cell
migration, we chose to use MDA-MB231, a highly migrated and invasive breast cancer
cells line in which group I PAKs was shown to be activated by phosphatidic acid (PA)
(Abramovici et al., 2009). Endogenous ERK3 was knocked down by stably expressing
shRNA specifically targeting ERK3 (Figure 8 ERK3 immunoblot, shERK3 versus
shGIPZ). Similar to what we found in A549 cells (Figure 7), ERK3 depletion greatly
reduced PAKs’ phosphorylations on these activating serine/threonine residues under
conditions with or without PA stimulation in MDA-MB 231 cells. These results suggest
that the positive regulation of group I PAKs’ phosphorylations/activation by ERK3 occurs
in different types of cancer cells.
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Figure 8: ERK3 upregulates group I PAKs’ phosphorylations in MDA-MB 231 cells.
MDA-MB 231 cell line with stable knockdown of ERK3 (ShERK3) and the control cell
line (ShGIPZ: non-targeting shRNA) were treated with 200µM /ml of Phosphatidic acid
(PA) or the BSA vehicle control for 25 minutes. Cells were then harvested and analyzed
using

western

blotting

for

PAK1/3(Thr423)/PAK2(Thr402)

group
and

I

PAKs

phosphorylation

anti-p-PAK1/3

(Ser144)/PAK2

respectively. β-Actin was probed to serve as a loading control.
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using

anti-p(Ser141),

v.

ERK3 affects the interactions of RhoGDI1 with PAK1 and Rac1/2/3.
To be activated by the action of GEF, Rho GTPases including Racs1/2/3 need to

first dissociate from RhoGDI1 (DerMardirossian et al. 2004). In addition, PAKs can
interact with and phosphorylate RhoGDI1, which promotes the dissociation of RhoGDI1
from Racs1/2/3 (DerMardirossian et al. 2004). As such, we wanted to investigate whether
ERK3 affects the interactions of RhoGDI1 with Rac1/2/3 and PAKs, by which ERK3
upregulates PAKs’ activation/phosphorylations. RhoGDI1 protein was overexpressed in
A549 stable cell pools, followed by immunoprecipitation of RhoGDI1 and Western
blotting analysis of the associated proteins (Figure 9). We found that while ERK3
overexpression had little effect on the interaction of RhoGDI1 with Rac1/2/3 (compare Rac
Blot in ERK3 lane versus that of CDH control lane in RhoGDI1 IP panel), it greatly
reduced the interaction of RhoGDI1 with PAK1 (compare PAK1 Blot in ERK3 lane versus
that of CDH control lane in RhoGDI1 IP panel). Interestingly, kinase-dead ERK3 (ERK3KD) increased RhoGDI1’s interaction with Rac1/2/3 but decreased its interaction with
PAK1. These results demonstrate that EKR3 affects the association/dissociation of
RhoGDI1 with Racs and PAK and that its kinase activity might be important in this
regulation.
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Figure 9: ERK3 affects the interactions of RhoGDI1 with PAK1 and Rac1/2/3 in A549
cells. pSG5-RhoGDI1-HA was transiently transfected into A549 stable cell pools that were
transduced with lentiviruses either expressing the CDH empty vector, wild type ERK3 or
kinase dead ERK3 (KD). IP was done using Anti-HA coated agarose beads, followed by
immunoblotting with antibodies against PAK1, RhoGDI1 and Rac1/2/3. Densitometry of
the PAK1 and Rac1/2/3 bands was performed. Numbers are the ratios of
immnoprecipitated PAK1 (PAK1(IP)/PAK1 input and the immunoprecipitated Rac (Rac
(IP)/Rac input.
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vi.

ERK3 upregulates the cellular levels of GTP-bound active Cdc42 and Rac1.
As GTP-bound Cdc42 and Rac1 GTPases are group I PAKs’ activators (Gatti et

al., 1998; Bagheri et al., 2000), we tested whether ERK3 promotes the activation of group
I PAKs via increasing the activities of Cdc42 and Rac1. First, we wanted to test this point
under the normal culture conditions (culture media with 10% FBS). As shown in Figure
10A, ERK3 knockdown indeed decreased the level of the GTP-bound active forms of both
Cdc42 and Rac1. We then examined the effect of ERK3 on the activation of Cdc42 and
Rac1 upon the stimulation with EGF. EGF greatly stimulated the activation of both Cdc42
and Rac1, as demonstrated by the remarkable increase of cellular levels of GTP-cdc42 and
GTP-Rac1 (EGF-Sictrl versus PBS-SiCtrl, Figure 10B). Knockdown of ERK3 decreased
the levels of GTP-Cdc42 and GTP-Rac1 (EGF-SiERK3 versus EGF-SiCtrl, Figure 10B).
These findings suggest that ERK3 positively regulate the activation of Cdc42 and RAC1
in A549 cells, which accounts for the increase of group I PAKs’ activation
(phosphorylations).
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Figure 10: Knockdown of ERK3 decreases the cellular levels of GTP-bound
Cdc42/RAC1 in A549 cells. (A) Cells were transiently transfected with either 20 nM nontargeting control siRNA (SiCtrl) or ERK3 siRNA (SiERK3). 2 days later, cells were
harvested and lysed. GTP-bound Cdc42 and Rac1 were pulled down following the
procedures as described in GTP-bound Cdc42/RAC1 activation assay in Materials and
Methods, followed by Western blotting using each specific antibody. Knockdown of ERK3
was verified by Western blot analysis of the total cell lysate. Numbers below the protein
bands are the quantification of protein levels by densitometry analysis. The band density
in “siCtrl” was set as 1. (B) A549 cells were transfected with either SiCtrl or SiERK3
siRNAs. Two days post transfection, cells were serum starved for 24 hours and then
treated with 50 ng /µl EGF for 10 minutes. Cellular levels of GTP-bound Cdc42 and Rac1
were then measured by GTP-bound Cdc42/RAC1 activation assay, followed by Western
blotting. Numbers below the protein bands are the quantification of protein levels by
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densitometry analysis. The band density in “PBS-siCtrl” was set as 1 and other are relative
to it.
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vii. Effects of ERK3 on RhoGDI1’s expression level in A549 cells.
We have found that ERK3 interacts and co-localizes with RhoGDI1 in lung cancer
cells and upregulates the activities of Cdc42 and Rac1. Therefore, we wondered whether
ERK3 regulates the expression level of RhoGDI1, thereby regulating the cellular level of
active small GTPases. We found that neither ERK3 knockdown (Figure 11A) nor overexpression (Figure 11B) affected the expression level of RhoGDI1, suggesting that ERK3
promotes Cdc42/Rac1 activation not through the downregulation of RhoGDI1’s expression
level.
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Figure 11: Effects of ERK3 on RhoGDI1’s expression level in A549 cells. (A) Cells
were transiently transfected with either 20 nM non-targeting control siRNA (SiCtrl) or
ERK3 siRNA (SiERK3). (B) Cells were transiently transfected with either 1 µg pSG5-HA
(empty vector) or pSG5-ERK3-HA. In both conditions, Cells were harvested and lysed 48
hours after transfection, and then analyzed by Western blotting for RhoGDI1 expression
using a RhoGDI1 specific antibody. β-Actin was probed to serve as a loading control.
Densitometry of the bands was performed and the ratio of RhoGDI1 to β -actin is displayed
in the figure.
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viii. ERK3 may phosphorylate RhoGDI1 in vitro.
It has been shown that phosphorylations of RhoGDI1 promotes its dissociation off
RhoGTPases and/or lowers the re-binding affinity of RhoGDI1 to RhoGTPases, leading to
the increased activation of Cdc42 and Rac1 (DerMardirossian et al. 2004). We thus tested
the possibility of ERK3 phosphorylating RhoGDI1. We performed in vitro ERK3 kinase
reaction using the purified RhoGDI1 (Figure 12A) as the substrate. In comparison with no
kinase control or the addition of kinase dead ERK3, the phosphorylation of RhoGDI1 was
increased by incubating with wild type ERK3 protein (autoradiograph of Figure 12B),
suggesting that RhoGDI1 is a potential substrate of ERK3 kinase.
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Figure 12: In vitro ERK3 kinase assay withRhoGDI1 as the substrate. (A) RhoGDI1
with a His tag was expressed in E. coli (BL21) cells, purified using nickel agarose beads
and analyzed by Coomassie staining on the SDS-PAGE gel. Lysate: total bacterial cell
lysate. Flow-through: the fraction of flowing through the nickel beads; Wash: the wash
buffer after the beads washing; Eluate: the proteins eluted off the beads at the final step of
purification. (B) In vitro kinase assay was performed by incubating 500 ng of purified
RhoGDI1-His protein (as a substrate) with 100 ng of purified wild type ERK3 protein
(ERK3 WT) or kinase-dead ERK3 mutant protein (ERK3-KD). Coomassie staining of the
proteins is shown in the left panel and autoradiograph of protein phosphorylations is
shown in the right panel.

43

ix.

ERK3 promotes lung cancer cell migration through promoting group I
PAKs’ activity in A549 cells.
ERK3 promotes cancer cell migration (Almahdi et al, 2015; Long et al 2012,). How

ERK3 promote cancer cell motility, however, is still unclear. Aforementioned results raise
an interesting idea that ERK3 may regulate cell migration through group I PAKs. To
determine whether ERK3 acts as an activator of group I PAKs, we examined the effects of
ERK3 overexpression on the phoshorylations of Rac1 and PAKs in A549 cells with or
without the treatment of FRAX597, an inhibitor of group I PAKs. As expected, ERK3
overexpression greatly increased phosphorylations of Rac1 and PAKs (ERK3/vehicle
versus EV/vehicle, Figure 13A). Importantly, FRAX597 treatment abolished the increase
of phosphorylations of Rac1 and PAKs stimulated by ERK3 overexpression
(ERK3/FRAX597 versus ERK3/vehicle, Figure 13A), confirming that ERK3 indeed
promotes PAKs’ kinase activity. We then tested the roles of ERK3 and PAKs in A549 cell
migration. In line with its role in regulating Rac1/PAKs’ activity (Figure 13A), ERK3
overexpression greatly increased A549 cell migration and this stimulating effect was
abolished by the treatment with FRAX597 (Figure 13B). These results clearly suggest that
ERK3 promotes A549 cell migration through activating PAKs.
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Figure 13: ERK3 promotes lung cancer cell migration through upregulating group I
PAKs’ activity. A549 cells were transfected with pcDNA-MYC (empty vector: EV) or
pcDNA-ERK3-MYC. 48 hours after transfection, cells were then treated with 400 nM of
either DMSO or FRAX 597 (group I PAKs inhibitor) for 16 hours. (A) Western blot
analyses of phosphorylations of PAKs (p-PAKs) and Rac1 (p-Rac1) and protein expression
levels. (B) Cell migration assay using a modified two-chamber transwell system.
Representative images of migrated cells with crystal violet staining are shown in the upper
panels. Quantified cell migration is presented as number of migrated cells per field (shown
in the lower panel).Values in bar graph represent mean ± S.D.
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IV.

Discussion

Extracellular signal-regulated kinase 3 (ERK3) is a member of the atypical
mitogen activated protein kinase (MAPK) subfamily. ERK3 possesses a single SEG
phospho-acceptor motif in its activation loop, instead of the TXY motif conserved in the
classic MAPKs, such as ERK1/2 (Coulombe and Meloche, 2007; Bind et al., 2004). In
comparison with the well-established ERK1/2 signaling cascade, much less is known about
ERK3 signaling. It has been shown that ERK3 is found to be overexpressed in multiple
types of cancer such as lung cancer (Long et al., 2012) and breast cancer (Almahdi et al.,
2015). Moreover, ERK3 has been shown to promote cancer cell migration and invasion
(Long et al., 2012; Almahdi et al., 2015). RhoGTPases, including Rho, Cdc42 and RAC1,
are important factors regulating cell morphology and motility (Ridley and Hall 1992;
Ridley et al, 1992; Raftopoulou and Hall 2004). RhoGDIs are Rho GTPase-GDP
dissociation inhibitor. They inhibit Rho-GTPases’ activities by rendering Rho-GTPases at
GDP-bound inactive status (Adra et al., 1997; Sasaki et al., 1998; Olofsson 1998;
Golovanov 2001). Cdc42 and RAC1, also known as p21 GTPases, activate group I PAKs
(p21 GTPase activated protein kinases) (PAK1, PAK2, PAK3) by binding to PAKs’ autoinhibitory domains and relieving PAKs’ auto-inhibition (Gatti et al., 1998; Bagheri et al.,
2000; Chong et al., 2001; Parrini et al., 2002; Pirruccello et al., 2006). Group I PAKs were
recently shown to phosphorylate ERK3 at S189 of the SEG activation motif (Déléris, et
al., 2011). In addition, proteomic analyses of ERK3-interacting proteins by Yeast-TwoHybrid screening (Y2H) and Immunoprecipitation-Mass spectrometry (IP-MS) revealed
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that ERK3 interacts with RhoGDI1 (Vinayagam et al., 2011). Taken together, these
findings suggest that ERK3 may be involved in RhoGDI1/ Rho GTPases/PAKs signaling,
by which it promotes cell morphology and migration.
In this study, we first verified the interactions of ERK3 with the RhoGDI1/Rho
GTPases/PAKs signaling complex. Co-immunoprecipitation assays demonstrated that
ERK3 and RhoGDI1 physically interact with each other at both endogenous and exogenous
conditions in A549 lung cancer cells. We then went further to investigate at which cellular
parts this interaction takes place and how it can influence cancer cell motility and
morphology. Previous studies have shown that ERK3, RhoGDI1, group I PAKs and Rho
GTPases are located both in the cytoplasm and at the plasma membrane and play roles in
controlling cell morphology and movement. Along with this, our immunofluorescence data
show that ERK3 co-localizes with RhoGDI1 and PAK1 in the cytoplasm and at the leading
edge of the plasma membrane. Moreover, ERK3 shows distinct co-localization with Cdc42
in the filopodia structure of HeLa and A549 cells. The sub-cellular distribution of these colocalized proteins provides strong indications that ERK3 is involved in RhoGDI1/
RhoGTPases/PAKs signaling and cooperatively control cancer cell morphology and
migration. Indeed, we then found that ERK3 upregulates the cellular levels of the active
forms of Cdc42 and Rac1 (GTP-Cdc42 and GTP-Rac1). In line with this, ERK3 promotes
the activating phosphorylations (activities) of group I PAKs presumably through increasing
the binding of active GTPases to PAKs. Interestingly, we further found that ERK3-induced
cancer migration was almost abolished by the inhibitors of group I PAKs. In conclusion,
these results clearly suggest that ERK3 promotes cancer cell migration through
upregulating group I PAKs signaling.
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Group I PAKs’ full activation is regulated by the phosphorylations at
Ser144/Ser141 and Thr423/Thr402 (Parrini et al., 2002; Pirruccello et al., 2006). To
elucidate the role of ERK3 on group I PAKs’ activation, we determined the
phosphorylation status of these residues under the conditions of either depletion of
endogenous EKR3 or exogenously overexpressing ERK3. We found that ERK3 positively
regulates PAKs’ phosphorylations at Ser144/Ser141 and Thr423/Thr402 with minor
changes on total PAKs’ levels. Overall, these findings do suggest that ERK3 promotes
group I PAKs’ activation, but does not affect no PAK 1/2 /3’s expression. Furthermore,
we confirmed these results in another type of MDA-MB231 breast cancer cells, indicating
that the upregulation of group I PAKs’ activation by ERK3 occurs in different types of
cancers.
GTP-bound active forms of Rho GTPases bind to and activate group I PAKs. In
order to bind to PAKs, Cdc42/Rac1 must first be dissociated from RhoGDI1 for the
subsequent activation by GEF. Phosphorylations of RhoGDI1 alter its conformation and
promote its dissociation from GDP-Cdc42 and GDP-Rac1. For example, RhoGDI1 is
known to be phosphorylated by PAK1 at S101 and S174, which promotes the dissociation
of GDP-Cdc42 and GDP-Rac1 off RhoGDI1 (DerMardirossian et al. 2004). As ERK3
interacts with RhoGDI1 and upregulate the cellular level of the active form of Rho
GTPases, we thus postulated that ERK3 may phosphorylate RhoGDI1 leading to the
release of GDP-Cdc42 and GDP-Rac1 and their subsequent activation. On one hand, this
idea was supported by our preliminary data showing that RhoGDI1 appears to be
phosphorylated by ERK3 in vitro. It is certainly important to further confirm RhoGDI1’s
phosphorylation by ERK3 and to identify the specific phosphorylation site(s). On the other
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hand, we found that overexpression of wild type ERK3 had little effect on the interactions
of Rac1/2/3 with RhoGDI1, whereas overexpression of catalytically inactive ERK3
(ERK3KD) greatly increased (by 2 folds) the interaction of Rac1/2/3 with RhoGDI1. A
possible explanation for this is that as A549 cells has high level of endogenous wild type
ERK3, ERK3’s role in regulating the interaction of RhoGDI1 with Rac1/2/3 might not be
affected by additional exogenous expression of wild type ERK3; however, ERK3KD could
act as a dominant negative mutant of wild type ERK3 and brings about great change.
Surprisingly, both ERK3 and ERK3KD greatly reduced the interaction of RhoGDI1 with
PAK1. While we currently do not know whether this is related to the activation of PAKs,
it is important to determine the effects of ERK3KD on the activities of Cdc42/Rac1 and
PAKs.
ERK3 localizes in the nucleus and the cytoplasm (Déléris et al., 2008) and at the
plasma membrane (Almahdi et al., 2015). While it is known that ERK3 nuclear export to
the cytoplasm is mediated by CRM1 (Déléris, et al., 2008), it is unclear how ERK3 is
translocated to the plasma membrane. RhoGTPases Rac1 and Cdc42 can transport proteins
in the nucleus and/or cytoplasm (e.g., nuclear protein SET) to the plasma membrane to
promote cancer cell migration (Klooster et al., 2007; Lerida et al., 2015). Interestingly, our
current study shows that ERK3 co-localizes with Cdc42 and PAK1 at the leading edge of
the plasma membrane. Taken all these together, we speculate that RhoGTPases mediate
ERK3’s translocation to the plasma meterman to promote cancer cell motility. We will be
testing this idea in our future work.
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In

summary,

our

present

study

shows

that

ERK3

interacts

with

RhoGDI1/RhoGTPases/PAKs signaling complex at the leading edge of plasma membrane,
activates Cdc42 and RAC1 and subsequently group I PAKs, thereby promoting cancer cell
migration. For future work, we plan to elucidate: 1) how EKR3 is translocated to the
leading edge of the plasma membrane; 2) the underlying mechanisms by which ERK3
activates RhoGTPases; 3) the role of ERK3 and PAKs cooperatively promoting tumor
formation and metastasis.

Figure 14: A working model of how ERK3 promotes cancer cell migration through
upregulating group I PAKs’ activity.
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